Kite Pharma, a biotech developing a cancer drug that utilizes the immune system, filed on Monday with the SEC to raise up to $115 million in an initial public offering. The Santa Monica, Ca-based company, which was founded in 2009, plans to list on the NASDAQ...read more
SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, announced terms for its IPO on Wednesday. The Durham, NC-based company plans to raise $55 million by offering 4.2 million shares at a price range of $12 to $14. At the midpoint of...read more
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Genocea Biosciences, which develops novel vaccines for infectious diseases through T cell immune responses, raised $66 million by offering 5.5 million shares at $12, at the low end of the range of $12 to $14. Genocea Biosciences plans to list on the NASDAQ under...read more
Immuno-oncology biotech Kite Pharma files for a $115 million IPO
Kite Pharma, a biotech developing a cancer drug that utilizes the immune system, filed on Monday with the SEC to raise up to $115 million in an initial public offering. The Santa Monica, Ca-based company, which was founded in 2009, plans to list on the NASDAQ...read more
Fungal infections biotech SCYNEXIS sets terms for $55 million IPO
SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, announced terms for its IPO on Wednesday. The Durham, NC-based company plans to raise $55 million by offering 4.2 million shares at a price range of $12 to $14. At the midpoint of...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Genocea Biosciences prices IPO at $12, the low end of the range
Genocea Biosciences, which develops novel vaccines for infectious diseases through T cell immune responses, raised $66 million by offering 5.5 million shares at $12, at the low end of the range of $12 to $14. Genocea Biosciences plans to list on the NASDAQ under...read more